Multiple Dates

Therapy and Research in Psychedelic Science (TRIPS) Seminar Series

Actions and Detail Panel


Event Information

Share this event

Date and time



Online event

Event description
TRIPS focuses on educating healthcare professionals about the latest innovations in therapy and research in psychedelic science.

About this event

TRIPS seminar series hosts speakers discussing scientifically-oriented presentations and discussions about psychedelics to educate healthcare professionals. This series was created to guide healthcare providers and students preparing to be professionals towards the most relevant, pragmatic, and essential information about psychedelic-assisted therapy, changing legal statuses, and harm reduction approaches in order to better serve clients and communities.

This seminar series is a fundraiser for our clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators plan to begin in the Fall of 2021. All proceeds after presenter remuneration will go to fund this clinical trial.

These presentations are hosted through Zoom. Each presentation will be approximately 30 minutes with a 30-minute discussion afterward. Presentations will be recorded and sent to anyone who registers for the event. The recording will be available for 30 days after it has been sent to registered attendees.

Cancellation Policy: We charge a $10 administration fee for cancellations made by participants more than two weeks before the training event. For cancellations within two weeks of the training event, we will refund 50% of the tuition after subtracting the administration fee. Alternately, participants may elect to apply 100% of their tuition to a future TRIPS training event. No refunds will be given after training events.

Upcoming Events:

January 14th, 2022 - Psilocybin-Assisted Therapy of Major Depressive Disorder using Acceptance and Commitment Therapy as a Therapeutic Frame with Jordan Sloshower, MD, MSc

Psychedelic-assisted therapy is based on the premise that psychedelic substances can act as catalysts or adjuncts to psychotherapeutic processes. Recent clinical trials involving psychedelic-assisted therapy have generally employed a similar three-part structure consisting of preparation, support during the dosing sessions, and subsequent “integration.” However, the content of these sessions and the frame through which the therapists approach participants and understand the clinical process has, thus far, been inconsistent among studies. In designing a manualized therapy protocol for a small clinical trial of psilocybin-assisted therapy for major depressive disorder, our group sought to delineate an explicit and replicable, evidence-based model that intentionally builds upon both the neurobiological actions of the medication and the phenomenology of the drug experience. Having identified considerable concordance in proposed mechanisms of change between Acceptance and Commitment Therapy (ACT) and psilocybin therapy, we employed ACT as an overarching psychotherapeutic framework. We hypothesize that the psilocybin experience can provide direct experiential contact with ACT processes that increase psychological flexibility, and that these deeply felt experiences may in turn be reinforced during ACT-informed follow-up therapy sessions. In this presentation, we describe the rationale for selecting ACT, areas of potential synergism between ACT and psilocybin therapy, the basic structure of our treatment model, and a case study using this approach. Relevant preliminary findings will also be shared.

Jordan Sloshower, MD, MSc is a psychiatrist and researcher in the Department of Psychiatry at Yale University. His research and clinical interests focus on therapeutic applications of psychedelic substances and in particular, how psychedelics can be combined optimally with psychotherapy and other healing modalities to treat a variety of conditions. Jordan is a co-founder of the Yale Psychedelic Science Group and is currently an investigator and therapist in two clinical trials of psilocybin-assisted therapy in the treatment of major depressive disorder. This research investigates potential neurobiological and psychological mechanisms of action, namely induction of neuroplasticity and psychological flexibility. He is also a clinical investigator in MAPS’ Expanded Access Program for MDMA-assisted therapy of PTSD. His perspective is informed by prior training in medical anthropology and global health, and deep interests in ethnobotany, Buddhist philosophy, and integrative approaches to wellness.


February 11th, 2022 - Drug-Drug Interactions Between Psychiatric Medications and MDMA or Psilocybin with Aryan Sarparast, MD

MDMA- and psilocybin-assisted therapies are moving through the Food and Drug Administration's drug development process for treatment of PTSD and Major Depressive Disorder (MDD), respectively. Many of those suffering from a mental illness are already on a psychiatric medication as treatment, some who have seen benefit and some who have not. What hasn't been clear is how psychiatric medications interact with psychedelics. Modern psychedelic studies require most psychiatric medications to be tapered off before starting MDMA- or psilocybin-assisted treatment, an approach that is common in underground psychedelic treatments. This poses unique challenges for vulnerable people who are placed in a position of having to pick between conventional treatment (e.g. SSRIs, lithium, etc.) and psychedelic treatment, oftentimes having to do this without appropriate support or education given that criminalization of psychedelic substances have led to limited research to inform practitioners. In this talk, I will present a summarization of all existing research on interactions between psychiatric drugs and MDMA or psilocybin. My aim is to educate attendees and share the knowledge necessary to keep vulnerable people safe. I will not be providing specific clinical advice or recommendations.

Aryan Sarparast, M.D. is an early-career psychiatrist who received his M.D. from the University of Central Florida College of Medicine and completed his residency training at Oregon Health and Science University (OHSU). He currently practices psychotherapy and pharmacotherapy of psychiatric illnesses as well as supervises psychiatry trainees learning psychotherapy. He is a research associate, under the direction of Chris Stauffer, in the Social Neuroscience and Psychotherapy Lab which is pending various projects on MDMA, psilocybin, and oxytocin. Aryan is saddened by the criminalization of psychedelics and the limitations of current psychiatric medication treatment which have led to a chasm between conventional psychiatric treatment and psychedelic-informed practitioners, a chasm that tends to most harm vulnerable people struggling with mental anguish. This inspired him to pursue his latest research project which systematically reviews the existing research on the interactions between psychiatric medications and MDMA or psilocybin; an effort to promote safety and knowledge.


May 13th, 2022 - Implementing Culturally-Attuned & Anti-Racist Psychedelic Therapy: Impact over Intention with Jamilah R. George, M.Div, M.S. (Rescheduled from December 2021)

As the field of psychedelic science continues to expand, psychedelic-assisted therapy is gaining an evidence base for its potential to treat a range of mental disorders. However, psychedelic science runs the risk of inflicting harm upon Black, Indigenous, and people of color (BIPOC) if it becomes widely accessible without acknowledging and dismantling the cultural insensitivities and historical exclusion embedded within it. This presentation will first briefly review the field of psychedelic science as it relates to limitations regarding cultural attunement and humility. It will also highlight the legacy of racism and exclusion of BIPOC in both the historical and present context of psychedelic treatment. Finally, the presenter will explore the implementation of treatment approaches that are intentionally culturally attuned and anti-racist as informed by an emotional harm reduction and social justice lens. *Note: Attendees are strongly encouraged to engage in discussion as much as possible and come prepared to practice transparency and vulnerability in a safe space designed to facilitate psychedelic therapy that is more accessible and equitable for everyone.

Jamilah R. George, M.Div., M.S. (pronunciation: Juh-MEE-luh), a native of Detroit, MI, obtained dual bachelor’s degrees from the University of Michigan and her master’s from Yale University. She is now a Clinical Psychology Ph.D. candidate at the University of Connecticut with a concentration in indigeneity, race, ethnicity, and politics (IREP). Jamilah also served as a study therapist of the Multidisciplinary Association for Psychedelic Sciences (MAPS) phase 3 clinical drug trial examining the efficacy of MDMA-assisted psychotherapy for treatment-resistant posttraumatic stress among people of color. She holds leadership positions in several professional organizations, including Chacruna’s Racial Equity and Access committee. Her research interests include obsessive-compulsive and related disorders, PTSD, the psychological effects of discrimination and racial trauma on people of color, and the neurological underpinnings of these disorders. Jamilah is also a Health Policy Research Scholar with the Robert Wood Johnson Foundation. Her passion for social justice and health equity fuels her work as she advocates for the mental and holistic wellbeing of socially disenfranchised groups, including women, people of color, impoverished domestic and international communities, and the intersections therein.

More dates will be announced soon!

Other Events Related to Psychedelics:

November 19th, 2021 - Ethical & Legal Considerations in Psychedelic Integration Therapy

Previous Events:

December 11th, 2020 - Ethical and Legal Considerations in Providing Psychedelic Integration Therapy with Brian Pilecki, Ph.D. and Jason Luoma, Ph.D.

January 8th, 2021 - What's It Like to Trip? The Patient Experience in Psychedelic-Assisted Therapy with Brian Pilecki, Ph.D.

February 12th, 2021 - Returning From All: Integrating 5-MeO-DMT Experiences in Psychotherapy with Rafael Lancelotta, M.S.

March 12th, 2021 - What does Psilocybin-Assisted Therapy for Depression Look Like? A Clinical Case Presentation based on a Recent Clinical Trial from Johns Hopkins with Alan K. Davis, Ph.D.

April 9th, 2021 - Ketamine 101: An Introduction to Ketamine-Assisted Psychotherapy with Gregory Wells, Ph.D.

May 14th, 2021 - Research on MDMA and Psychedelic-Assisted Therapy: An Overview of the Evidence for Clinicians with Jason Luoma, Ph.D.

June 11th, 2021- Becoming a Psychedelic-Informed Therapist: Toward Developing Your Own Practice with Nathan Gates, M.A., LCPC

September 10th, 2021- Cultural Considerations in Psychedelic-Assisted Psychotherapy with Terence Ching, PhD

October 8th, 2021- Psychedelic-Assisted Therapist Training: Current Perspectives and Look Forward with Dr. Elizabeth Nielson

November 12th, 2021- Psychedelic Research: Implications for Palliative Care and End-of-Life Existential Distress with Anthony Bossis, Ph.D.

Get Our Newsletter

Additional events for 2021 will be announced as they are scheduled. If you would like to stay up to date on information about TRIPS, you can join our newsletter here.

Portland Psychotherapy is also hosting an Ethical and Legal Considerations in Psychedelic Integration Therapy course in May of 2021. Check it out and sign up for it here.

Share with friends


Online event

{ _('Organizer Image')}

Organizer Portland Psychotherapy - Clinic, Research, & Training Center

Organizer of Therapy and Research in Psychedelic Science (TRIPS) Seminar Series

Portland Psychotherapy provides psychotherapy services, classes for personal growth, conducts scientific research, and provides training for professionals in evidence based psychotherapy approaches.

Save This Event

Event Saved